Review weighs GLP-1 agonists as adjunct therapy in hidradenitis suppurativa

The wire

1. 01The Expert Opinion on Therapeutic Targets review maps metabolic-inflammatory pathways in HS including insulin/IGF-1 signaling, mTORC1 overactivation, adipokine dysregulation and gut-skin interactions.
2. 02Authors suggest GLP-1 receptor agonists may help selected HS patients with obesity or metabolic syndrome by reducing systemic inflammation, perioperative risk and improving response to weight-based biologics.
3. 03Randomized trials with defined dermatological and metabolic endpoints are needed before routine use; reported reductions in pain and flares come from observational reports.

From the source

Molecular insights into GLP-1 receptor agonists and emerging metabolic-inflammatory targets in Hidradenitis suppurativa

Expert opinion on therapeutic targets · 2026 Sep 24 · Brogaard E, Nielsen VW, Pedersen NH et al.